Results 221 to 230 of about 9,828,326 (308)

Correction: Immunoinformatics-driven multi-epitope vaccine design targeting PSMA, STEAP1, and B7H3 for prostate cancer. [PDF]

Front Med (Lausanne)
Runtunuwu SVBE, Tallei TE, Kim HJ, Park MN, Celik I, Kirilmaz B, Turalaki GLA, Fatimawali F, Tendean LEN, Kaseke MM, Makawaehe DR, Rambi EV, Kim B.   +12 more
europepmc   +1 more source

Characteristics Associated With Persistent Long COVID Symptoms in Healthcare Personnel Infected With SARS‐CoV‐2 Between August 2022 and May 2024: A Multicenter Cohort Analysis of US Healthcare Personnel

American Journal of Industrial Medicine, EarlyView.
ABSTRACT Background Long COVID affects a significant proportion of COVID‐19 survivors. This study examined persistent Long COVID symptoms among healthcare personnel (HCP) and evaluated associations with vaccination, prior SARS‐CoV‐2 infection, underlying health conditions, and demographics.
Eric Kontowicz, Amanda K. Irish, Lilly C. Lee, Howard A. Smithline, Ian D. Plumb, Melissa Briggs‐Hagen, Alexandra F. Rollins, Karisa K. Harland, Anusha Krishnadasan, Karin F. Hoth, Eliezer Santos‐León, David A. Talan, Nicholas M. Mohr, Project PREVENT Network   +13 more
wiley   +1 more source

Mechanisms of Norovirus Immunity: Implications for Vaccine Design. [PDF]

Annu Rev Pathol
Ökten AB, Craft JE, Wilen CB.
europepmc   +1 more source

Lost and Found: Is Olfactory Recovery More Promising After COVID‐19 Than Other Causes, Even 2 Years Later?

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Olfactory dysfunction is a hallmark feature of COVID‐19, yet the potential for recovery with long‐standing COVID‐19‐related smell loss (CRSL) remains uncertain, particularly when treatment is initiated years later. This study evaluated olfactory outcomes in patients with CRSL compared with non‐COVID‐19‐related smell loss (non‐CRSL),
John W. Hunsicker, Mabel Berg, Nicolaus Knight, Jessica W. Grayson, Bradford A. Woodworth, Justin H. Turner, Do‐Yeon Cho   +6 more
wiley   +1 more source

Systematic characterization of SARS-CoV-2 spike protein subunit trafficking and secretion reveals enhanced strategies for vaccine design and quantification. [PDF]

Front Microbiol
Zhang Q, Hammond M, Song J, Fang Z, Zhao H, Landström M, Mei YF.   +6 more
europepmc   +1 more source

Plant Virus Immunotherapy for HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

Advanced NanoBiomed Research, EarlyView.
Cowpea mosaic virus (CPMV) nanoparticles are safe and potent cancer immunotherapy candidates with strong immunomodulatory activity. CPMV activates innate immunity, which in turn drives adaptive immune responses and promotes durable, systemic antitumor effects.
Jessica Fernanda Affonso de Oliveira, Patrick Opdensteinen, Andrea Simms, Seongwon Jung, Giuliana P. Mognol, Hui Chen, Judith A. Varner, Nicole F. Steinmetz   +7 more
wiley   +1 more source

Site‐Specific Protein Bioconjugation Through Cellular Incorporation of Noncanonical Amino Acids

Angewandte Chemie, EarlyView.
Genetic code expansion (GCE) enables site‐specific installation of noncanonical amino acids containing bioorthogonal conjugation handles, allowing precise, homogeneous protein modification. This review examines the principles of orthogonal translation, surveys the chemistries available for chemoselective labeling, and highlights emerging multi‐site ...
Rahul Sarkar, Manas Joshi, Abhishek Chatterjee   +2 more
wiley   +2 more sources

Cryo-EM structure of African horse sickness virus VP2 receptor-binding protein enables nanoparticle vaccine design. [PDF]

Nat Commun
Martínez-Castillo A, Aebischer A, Toneatti P, Fu L, Vitour D, Sailleau C, Hoffmann B, Franzke K, Eschbaumer M, Weber S, Calvo Pinilla E, Ortego J, Gil-Cartón D, Bréard E, Zientara S, Kortekaas J, Beer M, Abrescia NG.   +17 more
europepmc   +1 more source

Rewriting Tumor Immunity With Bacterial Membrane Vesicles: A Versatile and Potent Therapeutic Strategy

Advanced NanoBiomed Research, EarlyView.
Bacterial membrane vesicles (BMVs) emerge as promising platforms for cancer immunotherapy owing to their intrinsic adjuvant properties and tunable cargo delivery capabilities. Their ability to modulate the tumor microenvironment, enhance antitumor immune responses, and support personalized therapeutic strategies highlights their growing potential as ...
Md Sifat Rahi, Md Mijanur Rahman, Asma Talukder, Urooj Yousaf Virk, Jennifer C. Wilson, Nigel McMillan, Ming Q. Wei   +6 more
wiley   +1 more source

Immunogenicity of poxvirus A16/G9 entry-fusion subcomplex and its restriction by A56/K2 protein informs vaccine design. [PDF]

Nat Microbiol
Yu H, Resch W, Cotter CA, Xiao W, Karamanolis T, Belghith AA, Ignacio MA, Earl PL, Cohen GH, Moss B.   +9 more
europepmc   +1 more source